1. Novel therapies for chronic myelogenous leukemia
Balkrishna N Jahagirdar, Jeffrey S Miller, Arun Shet, Catherine M Verfaillie 
Experimental Hematology 
Volume 29, Issue 5, Pages (May 2001)
DOI: /S X(01)

2. Figure 1
Signal transduction pathways affected by the p210BCR-ABL oncoprotein. Activation of the Ras, Jak/Stat, and PI-3 kinase pathways results in increased proliferation, normal differentiation, and decreased apoptosis of the CML progenitors. The FAK-Paxillin-F-actin-integrin pathway impairs adhesion to the marrow stroma and causes premature release of the CML progenitors into the circulation. STK = Serine Threonine Kinase
Experimental Hematology  , DOI: ( /S X(01) )

3. Figure 2
Targets of novel therapies for CML. Antisense oligonucleotides inhibit translation. Immunotherapies evoke responses against the p210BCR-ABL peptide. Tyrosine kinase (TK) inhibitors inhibit the TK function of p210BCR-ABL. Farnesyl transferase inhibitors inhibit activation of the Ras protein
Experimental Hematology  , DOI: ( /S X(01) )